Chimeric Receptors Targeting CD-19


Available for licensing are compositions and methods for targeting and destroying CD19-expressing cancers, especially B-cell malignancies such as lymphomas and leukemias.

The antibody used in this technology is called anti-CD19. CD19 antibodies have been used to treat people with lymphoma and Leukemia. This technology has changed the anti-CD19 antibody so that instead of floating free in the blood, its CD19-binding domain is now joined to a T cell. When an antibody is joined to a T cell in this way it is called a chimeric receptor. Once localized at a CD19-expressing cancer cell, the T-cell portion of the chimeric receptor stimulates an immune response to destroy the cancer cell.

Potential Commercial Applications: Competitive Advantages:
  • Therapeutic agents to treat or prevent CD19-expressing cancers, including B-cell malignancies.
 
  • Reduced toxicity and immunogenicity in humans of previous anti-CD19 chimeric receptors containing mouse sequences.


Development Stage:
  • Early-stage
  • In vitro data available


Inventors:

James Kochenderfer (NCI)  ➽ more inventions...


Intellectual Property:
US Application No. 15/315,533
PCT Application No. PCT/US2015/033473
US Application No. 62/006,313
US Application No. 16/360,281

Collaboration Opportunity:

The National Cancer Institute is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize chimeric antigen receptors targeting CD19. For collaboration opportunities, please contact John D. Hewes, Ph.D. at hewesj@mail.nih.gov.


Licensing Contact:
David Lambertson, Ph.D.
Email: david.lambertson@nih.gov
Phone: 240-276-6467

OTT Reference No: E-042-2014-0
Updated: Oct 28, 2014